Retina ven tıkanıklığına bağlı maküla ödeminde intravitreal deksametazon tedavisinin etkinliği

References

1. 1. Ho M, Liu DT, Lam DS, Jonas JB. Retinal vein occlusions, from basics to the latest treatment. Retina. 2016; 36:432–448. 2. Rogers S, McIntosh RL, Cheung N, Lim L, Wang JJ, Mitchell P, Kowalski JW, Nguyen H, Wong TY: The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology. 2010;117: 313–319. 3. Wong TY., Scott IU. Clinicalpractice. Retinal-vein occlusion. N. Engl J. Med 2010; 363:2135-2144. 4. Campochiaro PA., Bhisitkul RB., Shapiro H., Rubio RG. Vascular endothelial growth factor promotes progressive retinal nonperfusion in patients with retinal vein occlusion. Ophthalmology.2013;120:795-802. 5. Felinski EA, Antonetti DA. Glucocorticoid regulation of endothelial cell tight junction gene expression: novel treatments for diabetic retinopathy. Curr Eye Res. 2005;30:949–957. 6. Nauck M, Karakiulakis G, Perruchoud AP, Papakonstantinou E, Roth M. Corticosteroids inhibit the expression of the vascular endothelial growth factor gene in human vascular smooth muscle cells. Eur J Pharmacol. 1998;341:309–315. 7. Ashraf M, Souka AAR: Steroids in central retinal vein occlusion: is there a role in current treatment practice? J Ophthalmol. 2015; 2015: 594615. 8. Yoshimura T, Sonoda KH, Sugahara M et al. Comprehensive analysis of inflammatory immune mediators in vitreoretinal diseases. PLoS One 2009;4:e8158. 9. Haller JA, Bandello F, Belfort R Jr, Ozurdex GENEVA Study Group et al. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion. Twelve-month study results. Ophthalmology. 2011;118:2453–2460. 10. Chang-Lin JE, Attar M, Acheampong AA et al. Pharmacokinetics and pharmacodynamics of a sustained release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci. 2011;52:80–86. 11. Manousaridis K, Peter S, Mennel S. Outcome of intravitreal dexamethasone implant for the treatment of ranibizumab-resistant macular edema secondary to retinal vein occlusion. Int Ophthalmol. 2017;37:47-53. 12. Michalska-Małecka K, Gaborek A, Nowak M, Halat T, Pawłowska M, Śpiewak D. Clin Interv Aging. 2016;11:699-705. 13. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97:1040–1044. 14. Yucel OE, Birinci H, Sullu Y. The short-term efficacy of intravitreal ranibizumab, aflibercept and dexamethasone implant in the treatment of macular edema due to non-ischemic central retinal vein occlusion. Int Ophthalmol. 2019;39:891-901.

Cited by

0 — Crossref — cited-by count (retrieved 2 Oct 2026, source)

Citation counts are shown with their source and retrieval date. They are not an Impact Factor or any journal-level metric.